Table 9 Base case results for patients with cirrhosis
From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
Genotype | Treatment | Duration (weeks) | Cost ($) | Effectiveness (QALYs) | ICER compared to benchmark ($/QALY) | Adjacent ICER ($/QALY) |
|---|---|---|---|---|---|---|
1 | Harvoni | 12 | 108,000 | 19.9787 | dominant | Â |
Telaprevir + Peginterferon + Ribavirin for first 12 weeks, followed by additional 12 or 36 weeks of Peginterferon + Ribavirin | 12 + 12 or 36 | 122,420 | 17.2075 | benchmark | dominated | |
Sofosbuvir + Peginterferon + Ribavirin (Treatment-naïve) | 12 | 130,750 | 17.8475 | 13,016 | dominated | |
Viekira Pak + Ribavirin | 24 | 186,820 | 19.7603 | 25,227 | dominated | |
Olysio + Sovaldi | 24 | 313,310 | 20.136 | 65,184 | 1,305,213 | |
2 | Peginterferon + Ribavirin (Treatment-naïve) | 24 | 81,070 | 15.874 | benchmark |  |
Initial: Peginterferon + Ribavirin; Follow-up: Sofosbuvir + Ribavirin for non-responders and relapsers. | 24 + 12 | 81,920 | 18.4461 | 330 | 330 | |
24 + 16 | 82,240 | 19.3293 | 339 | 362 | ||
Sofosbuvir + Ribavirin (Treatment-naïve) | 12 | 119,940 | 18.4217 | 15,257 | dominated | |
3 | Peginterferon + Ribavirin (Treatment-naïve) | 24 | 121,170 | 12.2543 | benchmark |  |
Initial: Peginterferon + Ribavirin; Follow-up: Sofosbuvir + Ribavirin for non-responders and relapsers. | 24 + 16 | 147,520 | 17.1869 | 5,342 | 5,342 | |
24 + 12 | 162,490 | 13.8563 | 25,793 | dominated | ||
Sofosbuvir + Ribavirin (Treatment-naïve) | 24 | 191,280 | 19.3615 | 9,865 | 20,123 |